- Home
- BIIB vs CCJ Comparison
BIIB vs CCJ Comparison
Compare BIIB & CCJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CCJ
- Stock Information
- Founded
- BIIB 1978
- CCJ 1987
- Country
- BIIB United States
- CCJ Canada
- Employees
- BIIB N/A
- CCJ N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CCJ Other Metals and Minerals
- Sector
- BIIB Health Care
- CCJ Basic Materials
- Exchange
- BIIB Nasdaq
- CCJ Nasdaq
- Market Cap
- BIIB 18.8B
- CCJ 16.7B
- IPO Year
- BIIB 1991
- CCJ N/A
- Fundamental
- Price
- BIIB $134.15
- CCJ $66.90
- Analyst Decision
- BIIB Buy
- CCJ Strong Buy
- Analyst Count
- BIIB 26
- CCJ 6
- Target Price
- BIIB $194.95
- CCJ $72.20
- AVG Volume (30 Days)
- BIIB 1.7M
- CCJ 5.9M
- Earning Date
- BIIB 07-31-2025
- CCJ 07-30-2025
- Dividend Yield
- BIIB N/A
- CCJ 0.17%
- EPS Growth
- BIIB 26.39
- CCJ 5.30
- EPS
- BIIB 10.12
- CCJ 0.40
- Revenue
- BIIB $9,816,400,000.00
- CCJ $2,290,088,704.00
- Revenue This Year
- BIIB N/A
- CCJ $8.11
- Revenue Next Year
- BIIB N/A
- CCJ $8.32
- P/E Ratio
- BIIB $13.31
- CCJ $169.20
- Revenue Growth
- BIIB 1.59
- CCJ 29.88
- 52 Week Low
- BIIB $110.04
- CCJ $35.00
- 52 Week High
- BIIB $238.00
- CCJ $68.12
- Technical
- Relative Strength Index (RSI)
- BIIB 62.26
- CCJ 83.55
- Support Level
- BIIB $129.61
- CCJ $57.63
- Resistance Level
- BIIB $134.74
- CCJ $60.97
- Average True Range (ATR)
- BIIB 3.10
- CCJ 1.92
- MACD
- BIIB 0.60
- CCJ 0.44
- Stochastic Oscillator
- BIIB 86.90
- CCJ 92.74
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.